-
1 Comment
NanoCarrier Co., Ltd is currently in a long term downtrend where the price is trading 12.9% below its 200 day moving average.
From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 57.9.
NanoCarrier Co., Ltd's total revenue sank by 60.6% to $56M since the same quarter in the previous year.
Its net income has dropped by 53.2% to $-369M since the same quarter in the previous year.
Based on the above factors, NanoCarrier Co., Ltd gets an overall score of 1/5.
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | JP3651120002 |
| CurrencyCode | EUR |
| Exchange | F |
| Market Cap | 107M |
|---|---|
| Dividend Yield | 0.0% |
| Target Price | None |
| PE Ratio | None |
| Beta | 0.69 |
NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's pipeline products includes ENT103, an antibacterial eardrops for the treatment of otitis media; NC-6300 Epirubicin micelle that is in phase I clinical trials; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was incorporated in 1996 and is headquartered in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 3NQ.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
